GlassScriptPhysician profile
Karen Creed
NPI 1063611101
$3,570.08
in general payments reported to CMS, 2019-2025
36 companies · $644 in 2025
The $644 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $290 · 2021: $239 · 2022: $424 · 2023: $494 · 2024: $439 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $661.99 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $557.61 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $410.01 | 2021-2025 | |
| Exeltis, USA INC. | $282.49 | 2022-2024 | Slynd |
| Amgen INC. | $234.46 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $210.00 | 2019-2025 | |
| Therapeuticsmd, INC. | $204.16 | 2019-2022 | |
| Optumhealth Care Solutions, LLC | $121.87 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Baxter Healthcare | $101.14 | 2024-2025 | Perclot |
| Coopersurgical, INC. | $78.76 | 2019-2025 | Paragard T 380a |
| Pfizer INC. | $78.24 | 2019 | |
| Novo Nordisk INC | $55.43 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $50.21 | 2024 | Myfembree |
| Exact Sciences Corporation | $49.80 | 2025 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $40.91 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $38.04 | 2019 | |
| Vertical Pharmaceuticals, LLC | $33.31 | 2019 | |
| Lupin INC. | $32.44 | 2020 | |
| Aspira Women'S Health INC | $29.26 | 2024 | Ova1 |
| Biogen, INC. | $28.86 | 2024 | Zurzuvae |
| Covidien LP | $27.62 | 2019 | |
| Avion Pharmaceuticals | $24.67 | 2020-2022 | |
| Smith+Nephew, INC. | $24.48 | 2025 | Pico 7, Pico 14 |
| Shield Therapeutics INC | $23.50 | 2024 | |
| Dexcom, INC. | $23.30 | 2025 | Dexcom G6 Transmitter |
| Channel Medsystems, INC. | $20.23 | 2025 | |
| Agile Therapeutics, INC. | $19.65 | 2022 | |
| Roche Diagnostics Corporation | $17.80 | 2019 | |
| Axonics, INC. | $14.64 | 2020 | |
| Merck Sharp & Dohme LLC | $14.13 | 2019 | |
| Novum Pharma, LLC | $13.00 | 2019 | |
| Avanos Medical | $12.59 | 2019 | |
| Acessa Health INC. | $12.53 | 2019 | |
| Virtus Pharmaceuticals LLC | $11.96 | 2022 | |
| Davol INC. | $10.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Creed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.